N-methylpyrid-3-ylestrone-16-methylcarboxamide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: N-methylpyrid-3-ylestrone-16-methylcarboxamide
• 英文别名: 2-[(8R,9S,13S,14S,16R)-3-hydroxy-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-16-yl]-N-(pyridin-3-ylmethyl)acetamide
• 化学式: C₂₆H₃₀N₂O₃
• 分子量: 418.536
• InChiKey: BTPQVHAQGIEPTN-IZZMWAHZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  79.3
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  雌酚酮 在 palladium on activated charcoal 4-二甲氨基吡啶 、 sodium hydroxide 、 氢气 、 potassium carbonate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 N-methylpyrid-3-ylestrone-16-methylcarboxamide
  参考文献：
  名称：

  Novel and Potent 17β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors

  摘要：

  Structure-based drug design using the crystal structure of human 17 beta-hydroxysteroid dehydrogenase type 1 (17 beta-HSD1) led to the discovery of novel, selective, and the most potent inhibitors of 17 beta-HSD1 reported to date. Compounds 1 and 2 contain a side chain with an m-pyridylmethylamide functionality extended from the 16 beta position of a steroid scaffold. A mode of binding is proposed for these inhibitors, and 2 is a steroid-based 17 beta-HSD1 inhibitor with the potential for further development.

  DOI：

  10.1021/jm049045r

文献信息

• Novel and Potent 17β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors
  作者：Harshani R. Lawrence、Nigel Vicker、Gillian M. Allan、Andrew Smith、Mary F. Mahon、Helena J. Tutill、Atul Purohit、Michael J. Reed、Barry V. L. Potter

  DOI：10.1021/jm049045r

  日期：2005.4.1

  Structure-based drug design using the crystal structure of human 17 beta-hydroxysteroid dehydrogenase type 1 (17 beta-HSD1) led to the discovery of novel, selective, and the most potent inhibitors of 17 beta-HSD1 reported to date. Compounds 1 and 2 contain a side chain with an m-pyridylmethylamide functionality extended from the 16 beta position of a steroid scaffold. A mode of binding is proposed for these inhibitors, and 2 is a steroid-based 17 beta-HSD1 inhibitor with the potential for further development.